摘要
目的观察曲美他嗪对冠状动脉粥样硬化性心脏病（冠心病）心力衰竭（心衰）患者血浆氮末端脑钠肽前体（NT．proBNP）水平及运动耐量的影响。方法冠心病心衰患者82例，完全随机分为曲美他嗪组及常规治疗组各41例，于开始治疗前及药物治疗6个月后测定NT-proBNP，并行超声心动图检查和6min步行试验，对2组不同时段相关数据进行比较。结果治疗后曲美他嗪组与治疗前及与常规治疗组治疗后相比，NT-proBNP水平明显下降（P〈0．05），左心室舒张末期容积明显缩小，而左心室射血分数显著增加（P〈0．05）；6min步行距离显著增加（P〈0．05）。结论曲美他嗪可改善冠心病心衰患者运动耐量，有效降低血浆NT-proBNP水平。
Objective To observe the influence of trimetazidine therapy on N-terminal pro-brain natriuretic peptide （NT-proBNP） and exercise tolerance in patients with congestive myocardial failure caused by coronary heart disease. Methods A total of 8 patients with congestive myocardial failure caused by coronary heart disease were randomized into trimetazidine group and routine therapy group, The levels of NT-proBNP, 2-dimensional echocardiography （DE） were detected and 6-mintute walk test was done for all patients at the baseline ancl 6 months after the therapy. Results The levels of NT-proBNP and LVEDV were significantly lower （ P 〈 0.05 ） , but LVEF became higher （ P 〈 0.05 ）, and the mean distance of 6-mintute walk test significantly increased （ P 〈 0.05 ） in trimetazidine group than those in routine therapy group ancl the baseline. Conclusion With trimetazicline therapy, the level of NT-proBNP decreases in patients with coronary heart disease complicated with congestive myocardial failure, meanwhile paitent＇s exercise tolerance is significantly improved.
出处
《中国医药》
2009年第2期89-90,共2页
China Medicine
